Autolus Therapeutics (NASDAQ:AUTL) Trading Up 4% – Still a Buy?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price rose 4% during mid-day trading on Friday . The company traded as high as $3.18 and last traded at $3.13. Approximately 2,001,397 shares changed hands during mid-day trading, an increase of 39% from the average daily volume of 1,438,985 shares. The stock had previously closed at $3.01.

Analyst Ratings Changes

AUTL has been the topic of a number of research reports. Needham & Company LLC restated a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Friday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.45.

Autolus Therapeutics Stock Up 3.0 %

The company has a 50-day moving average price of $3.92 and a two-hundred day moving average price of $3.99. The stock has a market capitalization of $824.88 million, a P/E ratio of -2.49 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the firm earned ($0.26) earnings per share. On average, sell-side analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC bought a new position in shares of Autolus Therapeutics in the second quarter worth approximately $43,000. Capstone Investment Advisors LLC bought a new position in shares of Autolus Therapeutics in the third quarter worth approximately $51,000. Bayesian Capital Management LP bought a new position in shares of Autolus Therapeutics in the first quarter worth approximately $100,000. Daiwa Securities Group Inc. grew its holdings in shares of Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Autolus Therapeutics in the first quarter worth approximately $108,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.